Clinical Trial Update: Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating safety, tolerability, and pharmacokinetics of multiple ascending doses of NIO752 in Progressive Supranuclear Palsy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Progressive Supranuclear Palsy

Drugs mentioned

• NIO752

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Progressive Supranuclear Palsy (PSP) | Phase 1 | Status: COMPLETED